Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Azienda Ospedaliero Universitaria Di Cagliari

Clinical trials sponsored by Azienda Ospedaliero Universitaria Di Cagliari, explained in plain language.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

Proteomics may unlock key clues to mepolizumab success in rare lung disease Results expected Oct 2026 (estimated)

Browse trials soon ready across all sponsors →

Not yet finished but already full! 1

Proteomics may unlock key clues to mepolizumab success in rare lung disease

Knowledge-focused By invitation only

This study aims to find biological markers in blood, saliva, and sputum that can predict how well patients with EGPA (a rare inflammatory disease) and severe asthma respond to the drug mepolizumab. Researchers will analyze proteins in these samples before and after treatment to u…

Phase 4 • Sponsor: Azienda Ospedaliero Universitaria di Cagliari • Aim: Knowledge-focused

Last updated Jun 27, 2026 08:11 UTC